Zimmer Biomet Earnings: Further Penetration of Rosa Robot Into ASCs Bodes Well

Wide-moat Zimmer Biomet posted solid third-quarter performance, and we’re holding steady on our fair value estimate, as the firm’s year-to-date results are tracking nearly on the nose with our full-year estimates. Although management adjusted its outlook slightly downward to account for foreign currency headwinds, our projections for the full year remain bounded by the new guidance.